<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gao H</submitter><funding>Natural Science Foundation of Shenzhen Municipality</funding><funding>Guangdong Basic and Applied Basic Research Foundation</funding><funding>Basic and Applied Basic Research Foundation of Guangdong Province</funding><funding>Longhua District Science and Technology Innovation Fund</funding><funding>Shenzhen Longhua District Science and Technology Innovation Fund</funding><pagination>871-883</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11967271</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>116(4)</volume><pubmed_abstract>The development of mesothelin (MSLN) epitope reactive T cells is observed in mice that are immunized with the MSLN vaccine. Engineered T cells expressing MSLN-reactive high-affinity TCR exhibit extraordinary therapeutic effects for invasive pancreatic ductal adenocarcinoma in a mouse model. However, the generation of MSLN-reactive T cells through the introduction of MSLN-deficient thymus and the transplantation of the latter as a cure for cancer treatment have not been tested to date. In the present study, the expression of MSLN was mainly identified in medullary thymic epithelial cells (mTECs) but not in hematopoietic cells, cortical thymic epithelial cells (cTECs), endothelial cells, or fibroblast cells in the thymus. The increasement of activated T cells was observed in MSLN-expressing </pubmed_abstract><journal>Cancer science</journal><pubmed_title>Transplantation of the MSLN-deficient Thymus Generates MSLN Epitope Reactive T Cells to Attenuate Tumor Progression.</pubmed_title><pmcid>PMC11967271</pmcid><funding_grant_id>11501A20220923BE5B6B3</funding_grant_id><funding_grant_id>2023A1515010171</funding_grant_id><funding_grant_id>11501A20220923BD5F291</funding_grant_id><funding_grant_id>2024013</funding_grant_id><funding_grant_id>JCYJ20220531092617039</funding_grant_id><pubmed_authors>Zhou L</pubmed_authors><pubmed_authors>Cao M</pubmed_authors><pubmed_authors>Chen P</pubmed_authors><pubmed_authors>Ning L</pubmed_authors><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Huang W</pubmed_authors><pubmed_authors>Chen F</pubmed_authors><pubmed_authors>Deng K</pubmed_authors><pubmed_authors>Gao H</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Song J</pubmed_authors><pubmed_authors>Wu H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transplantation of the MSLN-deficient Thymus Generates MSLN Epitope Reactive T Cells to Attenuate Tumor Progression.</name><description>The development of mesothelin (MSLN) epitope reactive T cells is observed in mice that are immunized with the MSLN vaccine. Engineered T cells expressing MSLN-reactive high-affinity TCR exhibit extraordinary therapeutic effects for invasive pancreatic ductal adenocarcinoma in a mouse model. However, the generation of MSLN-reactive T cells through the introduction of MSLN-deficient thymus and the transplantation of the latter as a cure for cancer treatment have not been tested to date. In the present study, the expression of MSLN was mainly identified in medullary thymic epithelial cells (mTECs) but not in hematopoietic cells, cortical thymic epithelial cells (cTECs), endothelial cells, or fibroblast cells in the thymus. The increasement of activated T cells was observed in MSLN-expressing </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-06-02T00:02:54.145Z</modification><creation>2025-07-11T03:03:53.928Z</creation></dates><accession>S-EPMC11967271</accession><cross_references><pubmed>39853704</pubmed><doi>10.1111/cas.16458</doi></cross_references></HashMap>